QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum
The immunomodulating ability of adjuvants has been shown to enhance immune responses directed both specifically and non-specifically against tumor development and growth and to increase immune response to weak antigens. This study compared two adjuvants, alum and QS-21, given separately and together in a candidate p17-based subunit AIDS vaccine, HGP-30-KLH. Alum, the only adjuvant approved for human use, confers a particulate appearance to the immunogen by adsorbing it and retains the immunogen in the body.1 QS-21 is a pure triterpene glycoside saponin adjuvant,2 and is purified from the total saponin fraction of Quillaja saponaria Molina. Crude mixtures of Quillaja saponaria saponins serve as the matrix component of the immunostimulating complex (ISCOM).3 The study’s hypothesis was that these two adjuvants function by different means to increase antibody titer to a synthetic peptide immunogen. QS-21, with its biochemical as well as physical properties, was expected to generate a greater antibody response than alum, and the two combined may be additive or synergistic.
KeywordsHuman Immunodeficiency Virus Human Immunodeficiency Virus Type Average Optical Density Human Immunodeficiency Virus Vaccine Increase Antibody Titer
Unable to display preview. Download preview PDF.
- 2.Kensil, C.R., Patel, U., Lennick, M., and Marciani, D., “Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex,” J. Immunology 146:431–437, 1991.Google Scholar
- 5.Jaing, J.D., Chu, F.N., Naylor, P., Kirkley, J., Mandelli, J., Wallace, J.I., Sarin, P., Goldstein, A., and Bekesi, J.G., ‘Antibody responses to synthetic epitopes of HIV-1 gag p17 in different stages of HIV-1 infection in homosexuals and IV drug abusers,’ Proc. Natl. Acad. Sci. (submitted).Google Scholar
- 6.Wahren, B., Rosen, J., Sandstrom, E., Mathiesen, T., Modrow, S., and Wigzell, H., ‘HIV-1 peptides induce a proliferative response in lymphocytes from infected persons,’ J. AIDS 4:448–456, 1989.Google Scholar
- 8.Goldstein, A.L., Naylor, P.H., Sarin, P.S., Kirkley, J.E., Stambuk, D., and Rios, A., ‘Progress in the development of a p17 based HIV vaccine: immunogenicity of HGP-30 in humans,’ Abstract S.A.76, VI International Conference on AIDS, San Francisco, Calif., U.S.A., 1990.Google Scholar
- 11.Goldstein, A.L., Naylor, P.H., Kirkley, J.E., Naylor, C.W., Gibbs, C.J., and Sarin, P.S., ‘Evaluation of a synthetic HIV-1 p17-based candidate AIDS vaccine, HGP-30,’ Abstract M.C.P.13, V International Conference on AIDS, Montreal, Quebec, Canada, 1989.Google Scholar
- 12.Naylor, P.H., Naylor, C.W., Badamchian, M., Wada, S., Goldstein, A.L., Wang, S.-S., Sun, D., Thorton, A.H., and Sarin, P., ‘Human immunodeficiency virus containing an epitope immunoreactive with thymosin alpha 1 and the thirty amino acid synthetic p17 group specific antigen peptide HGP30,’ PNAS 84:2951–2955, 1986.CrossRefGoogle Scholar